CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today issued a letter to shareholders to give an update on third quarter 2017 and ongoing MyoPro® commercial activities.
An accompanying digital shareholder letter can be viewed at: shareholderletters.myomo.com/q3-17.
Dear Fellow Shareholders:
Welcome to the first edition of our Investor Relations digital shareholder letter, whose purpose is to keep you informed about Myomo's progress. Since completing our IPO in June, we have been implementing various sales and marketing programs to grow the company. We established additional MyoPro Centers of Excellence to distribute our products to patients around the country; increased our Marketing presence online and begun our international expansion. We are leveraging our FDA registered, CE Marked, and only commercial, proprietary technology to restore function to the millions of patients with upper limb paralysis.
We believe we have the strategic focus, business model, and an expanding operational footprint to ably serve this market, facilitating our growth.
Thank you for your investment in MYO shares, which provides us the resources to grow the business and create shareholder value over time.
Sincerely;
Paul R. Gudonis
Chairman & Chief Executive Officer
About Myomo
Myomo, Inc. is a commercial stage medical
robotics company that offers expanded mobility for those suffering from
neurological disorders and upper limb paralysis. Myomo develops and
markets the MyoPro product line. MyoPro is a powered upper limb orthosis
designed to restore function to the weakened or paralyzed arms of
patients suffering from CVA stroke, brachial plexus injury, traumatic
brain or spinal cord injury, ALS or other neuromuscular disease or
injury. It is currently the only marketed device that, sensing a
patient’s own EMG signals through non-invasive sensors on the arm, can
restore an individual’s ability to perform activities of daily living,
including feeding themselves, carrying objects and doing household
tasks. Many are able to return to work, live independently and reduce
their cost of care. Myomo is headquartered in Cambridge, Massachusetts,
with sales and clinical professionals across the U.S. For more
information, please visit www.myomo.com.
Forward Looking Statements
This press release contains
forward-looking statements regarding the Company's future business
expectations, including the launch of MyoPro for Veterans, which are
subject to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are only
predictions and may differ materially from actual results due to a
variety of factors. Our actual results could differ materially from
those anticipated in these forward looking statements for many reasons,
including, without limitation, risks related to regulatory approval and
market acceptance of our products, and the other risk factors contained
in our filings made with the Securities and Exchange Commission. More
information about factors that potentially could affect Myomo's
financial results is included in Myomo's filings with the Securities and
Exchange Commission. The Company cautions readers not to place undue
reliance on any such forward-looking statements, which speak only as of
the date made. The Company disclaims any obligation subsequently to
revise any forward-looking statements to reflect events or circumstances
after the date of such statements or to reflect the occurrence of
anticipated or unanticipated events.
